Laboratorio Reig Jofre, S.a. · BME:RJF
Laboratorio Reig Jofre — Reig Jofre — H1 2026 Earnings Presentation
15 slides from Laboratorio Reig Jofre's earnings presentation, 2026
Slide 1: Financial Results First Half 2026
Financial Results FIRST HALF 2026
Slide 2: Disclaimer
DISCLAIMER This presentation does not contain confidential material and may include publicly available market information that has not been independently verified by Reig Jofre. This information has been summarised and does not purport to be complete. The information contained in this presentation s
Slide 3: Key Milestones for Q2 2026
KEY MILESTONES FOR Q2 2026 Progress Supply chain operations Recovery of profitable in biotechnology normalised growth path integration in France and Belgium Plant and biosimilar Commissioning Strong growth of the new antibiotic of the latest launch of production line injectable dalbavancin Regulator
Slide 4: Sales by business unit
SALES By business unit SALES 1H 2026 €168 M +1% millions of euros 41% 40% 19% PHARMACEUTICAL SPECIALITY CONSUMER TECHNOLOGIES PHT PHARMACARE SPC HEALTHCARE CHC €69 MILLION / (2 %) €67 MILLION / +14 % €32 MILLION / (17%) Dermatology €16 M Antibiotics €25 M (11) % ENT RJ €7 M (3 %) (3 %) Osteoarticula
Slide 5: Sales by business unit: PHT, SPC, CHC
SALES By business unit SALES 1H 2026 €168 M +1% millions of euros 41% 40% 19% PHARMACEUTICAL SPECIALITY CONSUMER TECHNOLOGIES PHT PHARMACARE SPC HEALTHCARE CHC €69 MILLION / (2 %) €67 MILLION / +14 % €32 MILLION / (17%) • Following regulatory approval of the new • Osteoarticular grew by +23% , drive
Slide 6: International operations
INTERNATIONAL OPERATIONS SALES 1H 2026 €168 M +1% EUROPEAN LICENCE AGREEMENTS ADVANCED SERVICES SUBSIDIARIES (B2C) DISTRIBUTION(B2B) CDMO € 101 M € 37 M € 30 M PHT 60% 22% 18% SPC +2% (7%) +7% CHC RJ Nordics Direct sales driven by the eight European RJ UK subsidiaries grew by +2% RJ Czech Republic 7
Slide 7: Financial Results for 1H 2026: Profit and loss account
FINANCIAL RESULTS FOR 1H 2026 Profit and loss account millions of euros • Revenue stands at €168 million, up 1% on 2025, due to the Forté Income Gross margin Pharma’s supply chain temporary disruption. • Gross margin saw a €400K year- on- year improvement, coming in 10 basis points lower. 167 168 10
Slide 8: Balance sheet – Assets and investments at June 30
FINANCIAL RESULTS FOR 1H 2026 Balance sheet – Assets and investments at June 30 millions of euros ASSETS • Industrial investments are focused on the €75 million Investments € 20.9 M construction of Leanbio's new GMP manufacturing facility, the completion of the adaptation of INTANGIBLE ASSETS Indust
Slide 9: Balance sheet – Liabilities and debts at June 30
FINANCIAL RESULTS FOR 1H 2026 Balance sheet – Liabilities and debts at June 30 millions of euros LIABILITIES Gross Financial Debt Net Financial Debt €131 million FINANCIAL DEBT Q4 2025 Credit institutions 112 +29 FINANCIAL DEBT Other financial liabilities -9 Net debt-to-EBITDA FINANCIAL DEBT Q1 2026
Slide 10: RJF share performance YTD June 26
EVOLUCIÓN DE LA ACCIÓN RJFYTD jun 26 MARKET CAPITALISATION € 211 M RJF (ISIN ES0165359029) € 2,69/ Share - 30/06/2026 SHAREHOLDER COMPOSITION REIG JOFRE RJF YTD INVESTMENTS SL 6% 1% KAIZAHARRA + 5% 10% 6% CORPORACION 14% EMPRESARIAL SL ONCHENA, S.L. INVERSIONS L OLIVERA S.A. 63% Autocartera SCRIP DI
Slide 11: Alternative Performance Measures
ALTERNATIVE PERFORMANCE MEASURES Management uses certain alternative performance measures in making financial, operating and planning decisions, as well as to evaluate the performance of the Group and its subsidiaries. Management believes that these alternative performance measures provide additiona
Slide 12: Appendix I: Profit and loss account
APPENDIX I Profit and loss account millions of euros Sed ut perspiciatis INCOME STATEMENT (thousand euros) 30/06/2026 30/06/2025 V% Turnover 168.455 167.401 1% Cost of Sales (68.349) (67.685) 1% Gross margin 100.106 99.715 0% Work carried out for fixed assets 8.951 1.831 389% Other operating income
Slide 13: Appendix II: Balance sheet
Inventories 74.788 61.612 Trade and other receivables 70.894 65.285 Current tax assets 5.277 7.006 APPENDIX II Other current financial assets Other current assets 1.536 6.918 6.506 4.525 Balance sheet Cash and cash equivalents TOTAL CURRENT ASSETS 13.574 172.987 10.500 155.434 millions of euros TOTA
Slide 14: Links and additional information
LINKS AND ADDITIONAL INFORMATION FINANCIAL AND BUSINESS INFORMATION • Results | Laboratorio Reig Jofre NOTIFICATIONS TO THE CNMV (National Securities Market Commission) • Other relevant information | Laboratorio Reig Jofre NEWSLETTER SUBSCRIPTION CENTRE • Newsletter | Laboratorio Reig Jofre LATEST N
Slide 15: Contact details
C/ Gran Capitán, 10 08970 Sant Joan Despí BARCELONA, SPAIN T. +34 93 480 67 10 www.reigjofre.com www.reigjofre.com reigjofre.com